| Original language | English (US) |
|---|---|
| Pages (from-to) | 1139-1141 |
| Number of pages | 3 |
| Journal | European Journal of Heart Failure |
| Volume | 24 |
| Issue number | 6 |
| DOIs | |
| State | Published - Jun 2022 |
ASJC Scopus subject areas
- Cardiology and Cardiovascular Medicine
Access to Document
Other files and links
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
In: European Journal of Heart Failure, Vol. 24, No. 6, 06.2022, p. 1139-1141.
Research output: Contribution to journal › Letter › peer-review
}
TY - JOUR
T1 - Insulin resistance and incident heart failure
T2 - a meta-analysis
AU - Erqou, Sebhat
AU - Adler, Amanda I.
AU - Challa, Azariyas A.
AU - Fonarow, Gregg C.
AU - Echouffo-Tcheugui, Justin B.
N1 - Funding Information: Dr. Echouffo‐Tcheugui was supported by NIH/NHLBI grant K23 HL153774. Dr. Erqou is supported by Department of Veterans Affairs, Veterans Health Administration, VISN 1 Career Development Award. Prof. Adler is supported in part by the NIHR Oxford Biomedical Research Centre. Funding Information: Dr. Echouffo-Tcheugui was supported by NIH/NHLBI grant K23 HL153774. Dr. Erqou is supported by Department of Veterans Affairs, Veterans Health Administration, VISN 1 Career Development Award. Prof. Adler is supported in part by the NIHR Oxford Biomedical Research Centre. Conflict of interest: G.C.F. reports consulting for Abbott, Amgen, AstraZeneca, Bayer, Cytokinetics, Janssen, Medtronic, Merck, and Novartis. All other authors have nothing to disclose. The authors thank the United Kingdom Prospective Diabetes Study (UKPDS) staff for providing us with the requested data. Dr. Echouffo-Tcheugui was supported by NIH/NHLBI grant K23 HL153774. Dr. Erqou is supported by Department of Veterans Affairs, Veterans Health Administration, VISN 1 Career Development Award. Prof. Adler is supported in part by the NIHR Oxford Biomedical Research Centre. Conflict of interest: G.C.F. reports consulting for Abbott, Amgen, AstraZeneca, Bayer, Cytokinetics, Janssen, Medtronic, Merck, and Novartis. All other authors have nothing to disclose.
PY - 2022/6
Y1 - 2022/6
UR - http://www.scopus.com/inward/record.url?scp=85132641474&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85132641474&partnerID=8YFLogxK
U2 - 10.1002/ejhf.2531
DO - 10.1002/ejhf.2531
M3 - Letter
C2 - 35502564
AN - SCOPUS:85132641474
SN - 1388-9842
VL - 24
SP - 1139
EP - 1141
JO - European Journal of Heart Failure
JF - European Journal of Heart Failure
IS - 6
ER -